News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Announces Progress On Global PARTHENON Clinical Trial Program With BRILINTA (ticagrelor) In High-Risk Cardiovascular Disease Patient Populations In Advance Of AstraZeneca PLC (AZN) Scientific Session



3/17/2014 8:42:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca (NYSE: AZN) today announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA® (ticagrelor) tablets. Part of PARTHENON, AstraZeneca’s largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States (US) from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES